Logo image of ONC.CA

ONCOLYTICS BIOTECH INC (ONC.CA) Stock Fundamental Analysis

Canada - Toronto Stock Exchange - TSX:ONC - CA6823108759 - Common Stock

1.42 CAD
+0.03 (+2.16%)
Last: 8/22/2025, 7:00:00 PM
Fundamental Rating

2

ONC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 23 industry peers in the Biotechnology industry. While ONC seems to be doing ok healthwise, there are quite some concerns on its profitability. ONC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ONC had negative earnings in the past year.
ONC had a negative operating cash flow in the past year.
In the past 5 years ONC always reported negative net income.
ONC had a negative operating cash flow in each of the past 5 years.
ONC.CA Yearly Net Income VS EBIT VS OCF VS FCFONC.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

ONC's Return On Assets of -152.26% is in line compared to the rest of the industry. ONC outperforms 45.83% of its industry peers.
Looking at the Return On Equity, with a value of -499.46%, ONC is in line with its industry, outperforming 54.17% of the companies in the same industry.
Industry RankSector Rank
ROA -152.26%
ROE -499.46%
ROIC N/A
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ONC.CA Yearly ROA, ROE, ROICONC.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONC.CA Yearly Profit, Operating, Gross MarginsONC.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ONC has more shares outstanding
ONC has more shares outstanding than it did 5 years ago.
ONC has a worse debt/assets ratio than last year.
ONC.CA Yearly Shares OutstandingONC.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ONC.CA Yearly Total Debt VS Total AssetsONC.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -33.32, we must say that ONC is in the distress zone and has some risk of bankruptcy.
ONC has a Altman-Z score (-33.32) which is in line with its industry peers.
A Debt/Equity ratio of 0.10 indicates that ONC is not too dependend on debt financing.
ONC's Debt to Equity ratio of 0.10 is fine compared to the rest of the industry. ONC outperforms 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -33.32
ROIC/WACCN/A
WACCN/A
ONC.CA Yearly LT Debt VS Equity VS FCFONC.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 2.88 indicates that ONC has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.88, ONC is doing good in the industry, outperforming 66.67% of the companies in the same industry.
ONC has a Quick Ratio of 2.88. This indicates that ONC is financially healthy and has no problem in meeting its short term obligations.
ONC has a better Quick ratio (2.88) than 70.83% of its industry peers.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.88
ONC.CA Yearly Current Assets VS Current LiabilitesONC.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.63% over the past year.
EPS 1Y (TTM)2.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ONC will show a very strong growth in Earnings Per Share. The EPS will grow by 25.19% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.99%
EPS Next 2Y6.67%
EPS Next 3Y10.11%
EPS Next 5Y25.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONC.CA Yearly Revenue VS EstimatesONC.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ONC.CA Yearly EPS VS EstimatesONC.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ONC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ONC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONC.CA Price Earnings VS Forward Price EarningsONC.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONC.CA Per share dataONC.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.67%
EPS Next 3Y10.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ONC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCOLYTICS BIOTECH INC

TSX:ONC (8/22/2025, 7:00:00 PM)

1.42

+0.03 (+2.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-10 2025-11-10/amc
Inst Owners1.52%
Inst Owner ChangeN/A
Ins Owners4.01%
Ins Owner ChangeN/A
Market Cap126.12M
Revenue(TTM)N/A
Net Income(TTM)-30.41M
Analysts77.5
Price Target4.6 (223.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.91%
Min EPS beat(2)20.79%
Max EPS beat(2)35.03%
EPS beat(4)3
Avg EPS beat(4)14.8%
Min EPS beat(4)-15.35%
Max EPS beat(4)35.03%
EPS beat(8)6
Avg EPS beat(8)14.12%
EPS beat(12)8
Avg EPS beat(12)8.97%
EPS beat(16)11
Avg EPS beat(16)10.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.58%
PT rev (3m)0.24%
EPS NQ rev (1m)9.37%
EPS NQ rev (3m)12.12%
EPS NY rev (1m)20.83%
EPS NY rev (3m)20.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 20.71
P/tB 20.71
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -152.26%
ROE -499.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.88
Altman-Z -33.32
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.58%
Cap/Depr(5y)28.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y21.99%
EPS Next 2Y6.67%
EPS Next 3Y10.11%
EPS Next 5Y25.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.16%
EBIT Next 3Y5.76%
EBIT Next 5Y42.82%
FCF growth 1Y6.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.92%
OCF growth 3YN/A
OCF growth 5YN/A

ONCOLYTICS BIOTECH INC / ONC.CA FAQ

What is the ChartMill fundamental rating of ONCOLYTICS BIOTECH INC (ONC.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ONC.CA.


Can you provide the valuation status for ONCOLYTICS BIOTECH INC?

ChartMill assigns a valuation rating of 0 / 10 to ONCOLYTICS BIOTECH INC (ONC.CA). This can be considered as Overvalued.


How profitable is ONCOLYTICS BIOTECH INC (ONC.CA) stock?

ONCOLYTICS BIOTECH INC (ONC.CA) has a profitability rating of 1 / 10.


Can you provide the financial health for ONC stock?

The financial health rating of ONCOLYTICS BIOTECH INC (ONC.CA) is 4 / 10.